GlassScriptPhysician profile
Boris Mayzler
NPI 1417038753
$3,578.80
in general payments reported to CMS, 2019-2025
31 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $190 · 2021: $459 · 2022: $809 · 2023: $559 · 2024: $597 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $947.72 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $944.45 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $203.25 | 2019-2022 | |
| Axsome Therapeutics, INC. | $185.19 | 2022-2024 | Auvelity |
| Scilex Pharmaceuticals INC. | $185.03 | 2022-2024 | Ztlido |
| Novo Nordisk INC | $155.76 | 2022-2023 | |
| Pfizer INC. | $114.61 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $82.01 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.27 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.28 | 2019-2024 | Ofev |
| Astellas Pharma US INC | $54.47 | 2025 | Veozah |
| Genentech USA, INC. | $48.64 | 2019-2022 | |
| Abbott Laboratories | $40.16 | 2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $39.71 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.74 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35.38 | 2022-2023 | Emgality, Jardiance |
| Aimmune Therapeutics, INC. | $34.65 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $34.47 | 2019 | |
| Ironwood Pharmaceuticals, INC | $32.52 | 2023-2025 | Linzess |
| Azurity Pharmaceuticals, INC. | $30.30 | 2023 | Edarbi, Horizant |
| Medtronic, INC. | $29.72 | 2021-2022 | |
| Allergan, INC. | $29.46 | 2020 | |
| Medtronic Minimed, INC. | $24.73 | 2019 | |
| Janssen Biotech, INC. | $23.43 | 2019 | |
| Nabriva Therapeutics, Plc | $21.62 | 2020 | |
| Glaxosmithkline, LLC. | $20.80 | 2025 | Shingrix, Arexvy |
| Dexcom, INC. | $18.75 | 2021 | |
| Merck Sharp & Dohme LLC | $18.22 | 2019 | |
| Amgen INC. | $17.72 | 2025 | Tavneos |
| Circassia INC. | $14.95 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.79 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Mayzler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.